

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>Hippel James</u> _____ (Last) (First) (Middle) <u>614 MCKINLEY PLACE NE</u> _____ (Street) <u>MINNEAPOLIS MN 55413</u> _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIO-TECHNE Corp [ TECH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner Officer (give title below) _____ Other (specify below) _____ <p style="text-align: center;"><b>CFO</b></p>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/01/2023</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price				
Common Stock									57,561	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Options (Right to Buy)	\$31.26							(1)	08/09/2024	Common Stock 189,156		189,156	D	
Stock Options (Right to Buy)	\$44.33							(1)	08/08/2025	Common Stock 168,620		168,620	D	
Stock Options (Right to Buy)	\$47.6							(1)	08/07/2026	Common Stock 186,068		186,068	D	
Stock Options (Right to Buy)	\$66.97							(1)	08/05/2027	Common Stock 90,740		90,740	D	
Stock Options (Right to Buy)	\$66.97							(2)	08/05/2027	Common Stock 76,588		76,588	D	
Restricted Stock Units	(3)							(4)	(4)	Common Stock 7,780		7,780	D	
Stock Options (Right to Buy)	\$120.46							(4)	08/06/2028	Common Stock 30,400		30,400	D	
Stock Options (Right to Buy)	\$120.46							(5)	08/06/2028	Common Stock 40,536		40,536	D	
Restricted Stock Units	(3)							(6)	(6)	Common Stock 10,912		10,912	D	
Stock Options (Right to Buy)	\$94.52							(6)	08/15/2029	Common Stock 33,916		33,916	D	
Stock Options (Right to Buy)	\$94.52							(7)	08/15/2029	Common Stock 45,220		45,220	D	
Restricted Stock Units	(3)							(8)	(8)	Common Stock 12,798		12,798	D	
Stock Options (Right to Buy)	\$84.61							(8)	08/15/2030	Common Stock 34,442		34,442	D	
Stock Options (Right to Buy)	\$84.61							(9)	08/15/2030	Common Stock 45,923		45,923	D	
Restricted Stock Units	(3)	11/01/2023		A		26,318		(10)	(10)	Common Stock 26,318	\$0	26,318	D	

Explanation of Responses:

1. Fully exercisable.
2. Options to purchase 57,440 shares are vested. Options to purchase 19,148 shares vest on 8/5/2024.
3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
4. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 20,268 shares are vested. Options to purchase 10,136 shares vest on 8/6/2024 and options to purchase 10,134 shares vest on 8/6/2025.
6. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 11,304 shares are vested. Options to purchase 11,304 shares vest on each of 8/15/2025 and 8/15/2026 and options to purchase 11,308 shares vest on 8/15/2024.
8. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
9. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
10. 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025.

/s/ Andrew Nick as Attorney-in-  
Fact for James Hippel pursuant to 11/03/2023  
Power of Attorney previously filed

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**